Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2018’, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease

- The report reviews pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutics and enlists all their major and minor projects

- The report assesses Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Asklepion Pharmaceuticals LLC

AstraZeneca Plc

Bristol-Myers Squibb Co

Gilead Sciences Inc

Global Blood Therapeutics Inc

Modus Therapeutics AB

Novartis AG

NuvOx Pharma LLC

Pfizer Inc ...

Asklepion Pharmaceuticals LLC

AstraZeneca Plc

Bristol-Myers Squibb Co

Gilead Sciences Inc

Global Blood Therapeutics Inc

Modus Therapeutics AB

Novartis AG

NuvOx Pharma LLC

Pfizer Inc

Prolong Pharmaceuticals LLC

Seattle Genetics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Overview

Vaso-Occlusive Crisis ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Overview

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Companies Involved in Therapeutics Development

Asklepion Pharmaceuticals LLC

AstraZeneca Plc

Bristol-Myers Squibb Co

Gilead Sciences Inc

Global Blood Therapeutics Inc

Modus Therapeutics AB

Novartis AG

NuvOx Pharma LLC

Pfizer Inc

Prolong Pharmaceuticals LLC

Seattle Genetics Inc

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Drug Profiles

apixaban – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

crizanlizumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inclacumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

L-Citrulline – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVX-508 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

regadenoson – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rivipansel sodium – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sanguinate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sevuparin sodium – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGN-2FF – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ticagrelor – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Dormant Projects

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Discontinued Products

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Product Development Milestones

Featured News & Press Releases

Jan 09, 2018: Prolong Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference

Dec 13, 2017: Prolong Pharma Announces Completion of Enrollment in Phase II Study of SANGUINATE in the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis in an Ambulatory Setting

Nov 08, 2017: Prolong Pharmaceuticals to Present New Research on SANGUINATE, an Investigational Treatment Under Evaluation for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease, at ASH Annual Meeting

Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis

Oct 29, 2015: GlycoMimetics Announces Initiation of First Clinical Trial Evaluating Subcutaneous Administration of Rivipansel

Oct 29, 2015: Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze Technology

Jun 23, 2015: GlycoMimetics to Receive $20 Million Payment from Pfizer Following Initiation of Phase 3 Trial with Rivipansel

Apr 07, 2015: GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015

Nov 06, 2014: GlycoMimetics Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting

Sep 26, 2014: GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel

Jul 01, 2014: GlycoMimetics Announces Agreement with FDA on Special Protocol Assessment for Phase 3 Clinical Trial of Rivipansel (GMI-1070)

May 21, 2014: GlycoMimetics Receives $15 Million Payment from Pfizer in Connection with Planned Initiation of Phase 3 Trial

Sep 13, 2013: GlycoMimetics Announces EMA’s Granting of Orphan Drug Status in European Union for GMI-1070 in Sickle Cell Disease

Aug 19, 2013: Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises

Jan 17, 2013: GlycoMimetics Completes Enrollment In Phase II Sickle Cell Disease Study With Lead Drug Candidate GMI-1070

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2018

Number of Products under Development by Companies ...

List of Tables

Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Asklepion Pharmaceuticals LLC, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by AstraZeneca Plc, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Bristol-Myers Squibb Co, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Gilead Sciences Inc, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Global Blood Therapeutics Inc, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Modus Therapeutics AB, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Novartis AG, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by NuvOx Pharma LLC, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Pfizer Inc, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Prolong Pharmaceuticals LLC, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Pipeline by Seattle Genetics Inc, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Dormant Projects, H2 2018

Vaso-Occlusive Crisis Associated With Sickle Cell Disease – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2018

Number of Products under Development by Companies ...

List of Figures

Number of Products under Development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports